Signia Pure C&G BCT IX vs Signia Pure C&G IX

The Signia Pure C&G BCT IX is a premium prescription behind-the-ear hearing aid released in 2025, priced at $3,398. In our lab testing, it earned an A grade with a SoundScore of 4.4/5, placing it in the top 39% of the 36 prescription hearing aids we've tested. This device shows notable strengths in speech clarity and own-voice comfort. Speech in quiet scored 3.8/5, which is 0.47 points above the category average—a solid result for everyday conversations. Speech in noise measured 2.5/5, above the category average by 0.58 points, though only mixed in absolute terms, meaning challenging listening environments may still present difficulty. Own-voice comfort is a standout at 3.8/5, a full 1.05 points above average, suggesting reduced occlusion effects that many wearers find bothersome. Feedback handling scored 4.2/5—strong in absolute terms, though 0.51 points below the category average of 4.71/5. Music streaming at 2.7/5 is essentially on par with category average. The device features rechargeable batteries, iPhone and Android streaming, and hands-free functionality. Consumers shopping in this premium price tier should note that several alternatives offer higher overall scores, including the Phonak Sphere Infinio (5.0/5) and Oticon Intent (4.85/5). For those prioritizing own-voice comfort and solid speech performance in quieter settings, the Pure C&G BCT IX delivers, but buyers seeking top-tier noise performance may want to compare options.

The Signia Pure C&G IX is a premium prescription behind-the-ear hearing aid released in 2023, currently available at $3,298. In HearAdvisor's lab testing, it earned an A grade with a SoundScore of 4.1/5, ranking #20 among 36 prescription hearing aids tested. This device demonstrates consistent strength across multiple performance areas. Speech in quiet scored a solid 4.0/5, sitting 0.65 points above the category average. Speech in noise performance, while above the category average by 0.25 points, remains mixed in absolute terms at 2.2/5—a common challenge across prescription devices. Feedback handling is a standout feature, achieving a perfect 5.0/5 and exceeding the already-high category average. Own-voice comfort scores a solid 3.2/5, running 0.45 points above the category average, which suggests good occlusion management. Music streaming performs solidly at 3.0/5, also above average for the category by 0.36 points. The device supports both iPhone and Android streaming along with hands-free functionality. Professional tuning yields meaningful improvement, with the normalized score increasing from 4.0/5 to 4.5/5. Buyers seeking top-tier performance in this price range should note that competitors like the Phonak Sphere Infinio (5.0/5) and Oticon Intent (4.85/5) scored higher in our testing. The Pure C&G IX may suit those who prioritize reliable feedback control and balanced everyday performance over maximum speech-in-noise capability.